ABSTRACT. To study the role of estrogen in the testes, testosterone and testicular steroidogenic enzyme mRNA levels were investigated in male Sprague-Dawley rats 24 hr after intramuscular administration of a single dose of estradiol-3-benzoate (EB). EB administration resulted in a greater decrease in intra-testicular and serum testosterone in 10-week-old rats than in 3-or 5-week-old rats. A dose of 2 µg EB/kg had the lowest observed effect. The level of serum luteinizing hormone (LH) was unchanged at any dose. Semiquantitative RT-PCR analysis revealed that, of the four major testicular steroidogenic enzymes, mRNA levels of cytochrome P450 side-chain cleavage and 17β-hydroxysteroid dehydrogenase type-III were significantly reduced, and mRNA levels of cytochrome P450 17α-hydroxylase/ C 17-20 lyase (P450c17) were reduced severely and significantly, by EB administration. However, the level of 3β-hydroxysteroid dehydrogenase type-I mRNA was not changed. In addition, the P450c17 mRNA level in EB-treated rats was much lower than that in the testes of hypophysectomized rats, with the level in the latter being equal to that in control rats. LH is secreted into blood periodically, the effects of estrogen on the LH secretion pattern of the pituitary gland, for example, in frequency and amplitude of LH pulse, were difficult to detect with the methods of the present study. The results indicated, at least, that EB administration down-regulates P450c17 gene expression predominantly, resulting in the inhibition of testosterone production. From the differences in the steroidogenic enzyme expressions between hypophysectomized and EB-treated rats, it was suggested that EB acts on the testis directly or indirectly though not via alteration of LH secretion and induces reduction of P450c17 mRNA level. KEY WORDS: estrogen, rat, steroidogenic enzyme, testis, testosterone.
It has been documented that estrogen receptor (ER) α is expressed in Leydig cells, rete testes, and efferent ducts [6] , and that ERβ is expressed in Sertoli cells and spermatogenic cells [32] . Eddy et al. found that testes in knockout mice lacking a functional ERα (ERKO) were atrophic with disruptions to the seminiferous epithelium and had gross dilations of the seminiferous tubule lumen in adulthood [5] .
Further studies on ERKO mice demonstrated that the disruption to spermatogenesis in this line was caused by a back pressure of fluid accumulating in the seminiferous tubules due to a lack of reabsorption of fluid in the efferent ductules, which were stimulated by estrogen in the normal male mouse [9] . These reports suggest that estrogen plays important roles in the male reproductive system.
Testosterone plays a fundamental role in spermatogenesis and is synthesized by Leydig cells in the testicular interstitium. Estrogen inhibits testosterone production in the testes of many vertebrates, human [18] , rat, frog [23] , and fish [8] . Both 17β-estradiol (E 2 ) and estradiol-3-benzoate (EB), a synthetic estrogen agonist, are known to have the same effect on testosterone production [2, 10, 15, 26, 27, 29] in rats. Although some investigators have documented that estrogen exerts its effects via direct action on the testes [15, 29] , it is generally thought that estrogen's effects are due to indirect action of E 2 via the hypothalamus and pituitary [2, 10, 26] . Leydig cells synthesize testosterone from cholesterol [22] . In male rat testes, cytochrome P450 side-chain cleavage (P450scc) first catalyzes cholesterol to produce pregnenolone [1, 25] , which is consequently catalyzed to progesterone by 3β-hydroxysteroid dehydrogenase (3β-HSD) [16] . Progesterone is then converted to androstendione by cytochrome P450 17α-hydroxylase/C 17-20 lyase (P450c17) [17] , and then to testosterone by 17β-hydroxysteroid dehydrogenase (17β-HSD) [19, 21] . The mechanism of estrogen-mediated inhibition of testosterone production, however, has not been well characterized at the gene expression level of the above four steroidogenic enzymes or with respect to endocrine signals such as the down-regulation of gonadotropin secretion.
In the present paper, we examined the effect of EB administration on testicular testosterone production and serum luteinizing hormone (LH) level by enzyme-immunoassay and semiquantitative RT-PCR measurement of steroidogenic enzyme mRNA levels in testes of adult male rats. In addition, based on a comparison of the testicular levels of the mRNA of these four enzymes with the corresponding levels in the testes of hypophysectomized rats, we discuss the potential mechanism of the estrogen-mediated inhibitory effect of testosterone production.
MATERIALS AND METHODS

Animals:
Male Sprague-Dawley rats (Jcl: SD; 3, 5, and 10 weeks old) and hypophysectomized rats (9 weeks old at sur-gery) of the same strain were purchased from CLEA Japan, Inc. (Tokyo, Japan). They were housed in a controlled environment with a 12 hr light/12 hr dark cycle at 24 ± 1°C and given food and water ad libitum. The rats were divided into 3 individuals per each experimental group, so, altogether, 36 rats were used in this study.
Administration: EB (99%; Sigma, St. Louis, MO, U.S.A.) was dissolved in corn oil (Sigma), and then administered intramuscularly to the rats at serial doses of 0.2 µg to 200 µg/kg body weight (bw). Twenty-four hours after the administration, serum was collected and testes were excised and stored at -80°C until use. The testes of hypophysectomized rats were dissected 6 weeks after surgery and then subjected to the same protocols as those of EB-treated rats.
Hormone assays: Testicular homogenate in 0.01 M phosphate-buffered saline (PBS, pH 7.4) was extracted with an appropriate volume of diethyl ether. The ether layer was evaporated by heating to 40°C, and then the dried-material was resuspended in EIA buffer packed into EIA Kits (Cayman Chemical Company, Ann Arbor, MI, U.S.A.). The testosterone level in the extract was measured by enzymeimmunoassay using EIA Kits according to the manufacturer's instructions. Intratesticular testosterone (ITT) was taken as the total amount of extracted testosterone from one testis divided by the testicular weight. Serum testosterone was measured by the same protocol. The LH level in serum was assayed using a Rat LH EIA system (Amersham Pharmacia Biotech, Buckinghamshire, England, UK) according to the manufacturer's instructions. The intra-and interassay coefficients of variation were, respectively, 5% and 9% for testosterone, 10.9% and 7.6% for LH.
Semiquantitative RT-PCR: Total RNA of the testis was extracted by the basic protocol of Chomczynski and Sacchi [4] . Two micrograms of total RNA were reverse-transcribed in a final volume of 10 µl containing 200 units SuperScript TM II reverse transcriptase and 0.5 µg of Oligo(dT)12-18 Primer (Life Technologies, Rockville, MD, U.S.A.) at 42°C for 50 min by the standard protocol of the supplier. All PCRs for rat P450scc [20] , P450c17 [7] , 3β-HSD-type I [28] , 17β-HSD-type III [30] , and cyclophilin were carried out in 50 µl of PCR mixture containing 1.25 units of Ex Taq TM polymerase (TaKaRa Biochemicals, Otsu, Japan), 1 × Ex Taq TM buffer, 0.2 mM dNTP mixture, 2 pM of each primer, and 2 µl of the RT-product. The PCR conditions were as follows for all genes: an initial denaturation step at 94°C for 3 min and then cycling through denaturation at 94°C for 30 sec, annealing for 30 sec, extension at 72°C for 45 sec and a final extension step at 72°C for 5 min. Table 1 shows the primer sequences, annealing temperature, number of cycles, and product size for each gene in this experiment. The optimal number of cycles needed to semi-quantify the mRNA amount for each gene were determined by preliminary experiments using testicular total RNA from control rats. The PCR products were separated in 2% agarose gel. The relative amounts of RT-PCR products for P450scc, P450c17, 3β-HSD-I, and 17β-HSD-III were then quantified by standardizing with the PCR product of cyclophilin using Scion Images software (Scion Corporation, Frederick, MD, U.S.A.).
The PCR products for rat P450scc, P450c17, 3β-HSD-I, 17β-HSD-III, and cyclophilin were subcloned into pGEM-T Easy vector (Promega, Madison, WI, U.S.A.) and sequenced by the dideoxynucleotide chain termination method using an ABI Prism BigDye terminator cycle sequencing kit (PE-Biosystems, Foster City, CA, U.S.A.).
Statistical analysis: Statistical analyses were performed using StatView for Windows version 5.0 (SAS Institute, Cary, NC, U.S.A.). Statistical differences between control groups and EB treatment groups were determined by Student's t-test or one-way analysis of variance (ANOVA) followed by post hoc analysis using Fisher's PLSD test.
RESULTS
Effects on serum testosterone, intra-testicular testosterone, and LH level: Serum testosterone and intra-testicular testosterone levels increased between the ages of 3 and 10 weeks in an age-dependent manner, but the levels of 10 week-old rats were significantly increased compared with those of 3-and 5-week-old rats (Fig. 1) . Statistically significant decreases of serum testosterone and intra-testicular testosterone were detected at 24 hr after EB administration only in 10-week-old rats (p< 0.001, compared to the vehicle control group ) (Fig. 1) , with the reduction to 1/13 of control level in intra-testicular testosterone being more pronounced than that in serum testosterone (Fig. 1B) . The doseresponse relationship between EB dose and intra-testicular testosterone level was studied in 10-week-old rats. A clear dose-dependent decrease of intra-testicular testosterone was observed 24 hr after EB administration (Fig. 2 ). Even at 2 µg EB/kg bw, an approximate 60% reduction of intra-testicular testosterone level was observed (vehicle control, 149.74 ± 14.24 ng/g testis; 2 µg EB/kg bw, 55.24 ± 36.57 ng/g testis). In the groups receiving EB at a dose of greater than 20 µg EB/kg bw, intra-testicular testosterone level was reduced to about 10% of that in controls (20 µg EB/kg bw, 15.28 ± 3.33 ng/g testis; 200 µg EB/kg bw, 10.92 ± 1.49 ng/ g testis).
Serum LH levels were also measured at the same time point as testosterone levels (24 hr after EB treatment). There was, however, no alteration in serum LH concentration in any dose groups (Fig. 3A) , while serum testosterone levels showed dose-dependent reductions that were significant in 2 µg EB/kg bw and more dose groups (Fig. 3B) .
Effects on testicular steroidogenic enzyme mRNA levels: RT-PCR was used to measure changes in the mRNA levels of the four steroidogenic enzymes for testicular testosterone production. EB administration resulted in clear dose-dependent decreases of mRNA levels for P450scc, P450c17 and 17β-HSD-III (Fig. 4) . The mRNA level of P450c17 was especially reduced, showing a statistically significant decrease even at a dose of 2 µg EB/kg bw dose. However, the mRNA level of 3β-HSD-I was not changed in any of the EB-dose groups (Fig. 4) .
Comparison of the testicular steroidogenic enzyme mRNA levels between EB-treated and hypophysectomized rats: To determine whether or not the EB-induced downregulation of testicular steroidogenic enzyme mRNAs were dependent only on LH, the expression levels of these mRNAs in the hypophysectomized rat testes were compared with those of rats administered EB at a dose of 200 µg/kg bw. In the testes of hypophysectomized rats, levels of the mRNAs of P450scc and 17β-HSD-III were also significantly lower than those in vehicle controls (Fig. 5) . The as the mean ± SE (n=3). Statistically significant differences with the means between groups were analyzed by paired Student's t-test at each age (**, P<0.001). Fig. 2 . Dose-dependent effect of EB on ITT level in 10-week-old male rats. Data are given as the mean ± SE (n=3). Statistically significant differences in means from vehicle control (VC) were analyzed by ANOVA followed by Fisher's PLSD test (*, P<0.01; **, P<0.001).
level of 17β-HSD-III mRNA was undetectable in testes of the hypophysectomized rats. However, no differences were detected in the mRNA levels of either P450c17 or 3β-HSD-I mRNA between hypophysectomized and vehicle-treated rats.
DISCUSSION
The EB-induced reductions of testicular testosterone production observed in male rats in the present study were attributed to decreases in the levels of mRNAs for steroidogenic enzymes, and especially in mRNA for the cytochrome P450c17 gene. Intra-testicular testosterone was found to be a useful marker of the inhibitory effect of EB, since the magnitude of reduction as measured by intra-testicular testosterone was much greater than that measured by serum.
The increases of serum and intra-testicular testosterone levels between the ages of 3 and 10 weeks in an age-dependent manner (Fig. 1) agreed with previous reports [12, 31] . Our results also showed that EB-induced inhibition of testosterone production was more obvious in 10-week-old rats than in younger rats. In our preliminary data, we determined that testes of 10-week-old rats had a higher concentration of E 2 than those of 3-and 5-week-old rats (data not shown). In a previous report, mice lacking a functional aromatase that catalyzes synthesis of estrogens showed a tendency to higher serum testosterone concentrations than wild type mice [24] . These facts indicate that, in adult mice, endogenous E 2 may already suppress testosterone production and appropriate testosterone level is probably maintained by a balance between testosterone production and E 2 induced testosterone suppression.
Semiquantitative RT-PCR analysis revealed that EB treatment decreased the rat testicular levels of mRNAs of P450scc, P450c17, and 17β-HSD-III, but not that of 3β-HSD-I mRNA. Previous reports have shown that administration of E 2 reduced enzymatic activities of 17α-hydroxylase, C 17-20 lyase [3, 11] in rat testes. These findings are consistent with those of the present study, suggesting that the reductions in enzyme activities were due to the downregulation of P450c17 mRNA expression.
In general, many researchers accept the hypothesis that inhibition of testicular testosterone production by E 2 administration is mediated by a decrease of serum LH level through the action of E 2 on the hypothalamic-pituitary axis [10, 26] . In fact, in the report of Blanco-Rodriguez and Martinez-Garcia [2] , who administered EB using the same protocol as used here, the serum LH level was reduced to 1/ 3 of that before EB treatment, but serum testosterone was undetectable at days 1 through 5 after a single EB treatment. In our study, there was no significant difference in serum LH between the vehicle-and EB-treated groups at 24 hr after administration, when severe reductions of serum and intra-testicular testosterone levels were still observed. In previous papers, although intra-testicular testosterone level was decreased [29] , there was no change in serum LH level at 24 hr [27] and at 1 hr to 24 hr [29] after EB administration to adult male rats. These observations suggest that EB alone can inhibit testicular testosterone production even when LH level is not altered. LH is secreted into blood periodically, the LH pulse, and it has been reported that frequency and amplitude of the LH pulse were changed by the administration of E 2 [14] , which was difficult to detect in the present study because of insufficiency of the rat number in each group, n=3. EB-induced alterations of the LH pulse may affect on testicular testosterone production, and further studies are required.
Our results showed that the P450scc mRNA level of EBtreated rats was much lower than that of hypophysectomized Fig. 3 . Dose-dependent effect of EB on (A) serum LH and (B) serum testosterone levels in 10-week-old male rats. Data are given as the mean ± SE (n=3). Statistically significant differences in means from vehicle control (VC) were analyzed by ANOVA followed by Fisher's PLSD test (**, P<0.001).
rats. Furthermore, the P450c17 mRNA level was severely decreased by EB administration but was unaffected by hypophysectomy. It seems that serum LH levels of EBtreated rats are higher than those of hypophysectomized rats. Combining the pattern of steroidogenic enzyme mRNA expressions with the difference of the serum LH level between the EB-treated and hypophysectomised rats, it was highly suggestive that EB-induced inhibition of testicular testosterone production was due to not only LH alteration but also some other mechanism, possibly including a direct effect on the testes. It has also been reported that administration of E 2 to hypophysectomized rats with or without hCG treatment resulted in reductions of 17α-hydroxylase activities [11] and cytochrome P450 protein levels [3] . These reports also support our proposal that EB is able to effect on testicular testosterone production though not via alteration of LH secretion. Estrogen has been reported to inhibit testosterone production in porcine Leydig cells [13] and testicular tissue of rat [15] , human [18] , and frog [23] in vitro. EB may have a direct affect on testosterone production in Leydig cells, since ERα has been found in rat Leydig cells [6] . From the results of the present study, it remains unclear whether estrogen directly militates against testosterone production in Leydig cells. Further detailed investigations using a culture system of Leydig cells will be required.
